Market Closed -
Japan Exchange
02:00:00 2024-07-05 EDT
5-day change
1st Jan Change
4,200
JPY
-0.50%
+4.35%
+6.54%
Shimadzu : 1st Half Results & Financial Position for the Fiscal Year Ending March 2023
November 08, 2022 at 03:54 am
Shimadzu Corporation (TSE Prime Market: Securities code 7701)
1st Half FY 2022 (Ending March 2023) Results & Financial Position
President and Representative Director, CEO
November 8, 2022
Yasunori Yamamoto
Overview of Financial Results
01 Overview of Financial Results
2
Copyright © Shimadzu Corporation. All Rights Reserved.
1st Half FY 2022 (Ending March 2023) Results & Financial Position
Summary of Results
• AMI: Analytical & Measuring Instruments, MED: Medical Systems, IM: Industrial Machinery, AE: Aircraft Equipment
• AMI key models (LC: Liquid chromatographs, MS: Mass spectrometer systems, GC: Gas chromatographs), TMP: Turbomolecular pumps
3
Copyright © Shimadzu Corporation. All Rights Reserved.
1st Half FY 2022 (Ending March 2023) Results & Financial Position
Statement of Income
Q2 (Jul.-Sep.) results recovered, and H1 results achieved a record high
Net Sales
Operating Income
Operating Margin
Profit Attributable to
Owners of Parent
YoY: +19.8 bn yen / +10%
YoY: +0.1 bn yen / +0%
YoY: -1.3pt
YoY: +4.0 bn yen / +20%
221.9 bn yen
28.9 bn yen
13.0%
24.5 bn yen
Sales and Operating Income
Sales
Operating Income
1st Half (Apr.-Sep.)
YoY
Units: Billions of yen
over 5 years
OPM
(bn yen)
250.0
40.0
FY2020
FY2021
FY2022
Changes
%
221.9
202.1
36.0
182.9
186.5
Net Sales
178.8
202.1
221.9
+19.8
+10%
200.0
178.8
28.8
28.9
32.0
28.0
Business
Operating Income
19.6
28.8
28.9
+0.1
+0%
150.0
24.0
Operating Margin
11.0%
14.3%
13.0%
-1.3pt
17.4
17.9
19.6
Results
14.3%
20.0
Ordinary Income
19.5
29.4
33.1
+3.8
+13%
100.0
13.0%
16.0
11.0%
12.0
Profit Attributable to Owners of Parent
13.9
20.5
24.5
+4.0
+20%
9.5%
9.6%
50.0
8.0
4.0
Exchange
Average Rate: USD (Yen)
106.97
109.85
134.02
+24.17
+22%
Rates
Average Rate: Euro (Yen)
121.33
130.93
138.78
+7.85
+6%
0.0
0.0
FY2018 FY2019
FY2020
FY2021
FY2022
R&D Expenses
7.1
7.5
8.7
+1.2
Depreciation
Exchange Rate Effect
CAPEX
5.9
6.3
12.1
+5.8
and
Net sales: 19.5 bn yen Operating income: 5.1 bn yen
Amortization
8.5 bn yen
Exchange rate effect on overseas
inventory acted negatively.
4
Copyright © Shimadzu Corporation. All Rights Reserved.
1st Half FY 2022 (Ending March 2023) Results & Financial Position
Analysis of Increase/Decrease in Operating Income (Apr.-Sep.)
・ China lockdown impact cannot be fully resolved due to many installations required.
・ Proactively promote growth investment such as R&D and human resource investment. ・ Positive factors (improved productivity and price revision) surpassed negative factors (parts/materials price hike), and Gross Profit Margin improved.
(billions of yen)
Billions
H1
Q1
Q2
Remarks
・ Unrealized gain on
of yen
+5.1
+1.9
+3.2
Exchange Rate Effect
overseas inventory also
increased.
Gross Profit
+0.1
-1.2
+1.3
28.9
Increase/Decrease due to
28.8
Increased/Decreased Sales
Sales
Gross
Profit Decrease by Lockdown
(-1.5)
(-2.1)
(+0.6)
・ Recovering after July.
Exchange
Increase
R&D
(+1.6)
(+0.9)
(+0.7)
・ MED and IM sales
Profit
Increases in Sales
Rate
China
Expense
Human
Margin
increased.
Lockdown
Increase
Growth Investment
-3.7
-2.6
-1.1
・ Proactively promoted
ResourceImproved
R&D and Human
(-2.6)
Investment
Expense
Increase in Human Resource
(-2.0)
(-0.6)
Investment which were
Increase
Increase
Increase in R&D Expense
(-1.1)
(-0.6)
(-0.5)
curbed due to COVID-19
pandemic.
・ Positive factors
(improved productivity and
Gross Profit Margin Improved
+0.7
-0.1
+0.8
price revision) surpassed
negative factors
(parts/materials price
hike).
Expense Increased
-2.1
-1.0
-1.1
・ Logistics cost and
others increased.
5
Copyright © Shimadzu Corporation. All Rights Reserved.
1st Half FY 2022 (Ending March 2023) Results & Financial Position
This is an excerpt of the original content. To continue reading it, access the original document here .
Attachments
Original Link
Original Document
Permalink
Disclaimer
Shimadzu Corporation published this content on 08 November 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 08 November 2022 08:53:05 UTC .
Tranche Update on Shimadzu Corporation's Equity Buyback Plan announced on May 10, 2024.
07-05
CI
Shimadzu Corporation announces an Equity Buyback for 12,500,000 shares, representing 4.24% for ¥25,000 million.
05-10
CI
Shimadzu Corporation authorizes a Buyback Plan.
05-09
CI
Shimadzu Corporation acquired Gas chromatograph (GC) catalytic microreactor Business from Activated Research Company, LLC.
02-27
CI
Certain Common Stock of AR advanced technology, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.
12-18
CI
MiCAN Technologies Inc. announced that it has received ¥200 million in funding from RealTechJapan LLC., Fujimori Kogyo Co., Ltd., Shimadzu Corporation
23-08-06
CI
IMMUNOSENS Co. Ltd. announced that it has received funding from Global Brain Co., Ltd., Shimadzu Corporation
23-07-25
CI
AR advanced technology, Inc. has completed an IPO in the amount of ¥924.21 million.
23-06-23
CI
Shyld AI and Shimadzu Corporation Team Up with the Goal of Revolutionizing Healthcare with Groundbreaking AI-Powered UV-C Disinfection Technology
23-06-22
CI
Jefferies Adjusts Shimadzu's Price Target to 5,500 Yen From 5,000 Yen, Keeps at Buy
23-06-12
MT
Shimadzu Corporation acquired Biomaneo.
23-06-08
CI
AR advanced technology, Inc. has filed an IPO.
23-05-19
CI
Shimadzu Corporation Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-10
CI
Jefferies Adjusts Shimadzu's Price Target to 5,000 Yen From 5,500 Yen, Keeps at Buy
23-02-27
MT
New entries in the Asia Investor Portfolio
22-12-07
Shimadzu Corp. Shares Rise on Higher First-Half Profit
22-11-07
DJ
Shimadzu Corporation completed the acquisition of 34.7% stake in Nissui Pharmaceutical Co., Ltd. for ¥13.3 billion.
22-07-27
CI
Shimadzu Corporation made an offer to acquire a 45.9% stake in Nissui Pharmaceutical Co., Ltd. for ¥17.6 billion.
22-05-30
CI
Shimadzu Shares Rise Sharply After Fiscal-Year Net Profit Rose 31%
22-05-10
DJ
Rakuten Medical, Inc. and Shimadzu Corporation Enrolls First Patient in the U.S. Clinical Trial of Photoimmunotherapy
22-02-15
CI
Shimadzu Corporation Revises Earnings Guidance for the Year 2022
21-11-07
CI
Shimadzu Corporation Provides Interim and Full Year Dividend Guidance 2022
21-11-07
CI
Rakuten Medical and Shimadzu Corporation Announce A Joint Development and Commercialization Agreement
21-06-17
CI
Shimadzu Corporation Revises Earnings Guidance for the Fiscal Year Ending March 2021
21-02-05
CI
Shimadzu Corporation Plans to Pay Year End Dividend for the Fiscal Year Ending March 2021
21-02-05
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Shimadzu Corp is a Japan-based company mainly engaged in the research, development, manufacture, sale and maintenance of scientific and precision equipment. The Company has four segments. Testing and Measuring Instruments segment is engaged in the provision of chromatographic analysis systems, mass spectrometry systems, light analysis systems, thermal analysis systems, bio-related analysis systems, water quality measurement systems and others. Medical Equipment segment is engaged in the provision of X-ray television (TV) systems, angiography systems, X-ray imaging systems and others. Aircraft Equipment segment is engaged in the provision of flight control systems, air management systems, cockpit display systems and others. Industrial Equipment segment is engaged in the provision of turbomolecular pumps and others. The Company is also engaged in the leasing and management of real estate business.
More about the company
Last Close Price
4,200
JPY
Average target price
5,226
JPY
Spread / Average Target
+24.43%
Consensus
1st Jan change
Capi.
+6.54% 7.72B -7.40% 4.44B +2.43% 3.21B +14.68% 2.26B +11.48% 1.04B +11.18% 997M -42.62% 869M -61.05% 625M -35.27% 607M -31.73% 598M
Scientific & Precision Equipment
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1